Table 1.
Characteristics of patients with cutaneous reactions reported after Moderna or Pfizer COVID-19 vaccination
| Characteristic | Overall unique reports, n (%) | Moderna vaccine unique reports, n (%) | Pfizer vaccine unique reports, n (%) | p valuea |
|---|---|---|---|---|
| Patient age (mean, SD) | 48.42 (17.60) | 50.33 (16.51) | 45.51 (17.74) | < 0.0001 |
| Patient sex | < 0.0001 | |||
| Female | 54,107 (86.05) | 39,357 (88.39) | 14,750 (80.37) | |
| Male | 8279 (13.17) | 4862 (10.92) | 3417 (18.62) | |
| Past dermatologic history | ||||
| Psoriasis | 533 (0.85) | 316 (0.71) | 217 (1.18) | < 0.0001 |
| Urticaria | 312 (0.50) | 165 (0.37) | 147 (0.80) | < 0.0001 |
| Atopic dermatitis | 37 (0.06) | 17 (0.04) | 20 (0.11) | 0.0009 |
| Acne vulgaris | 30 (0.05) | 17 (0.04) | 13 (0.07) | 0.0882 |
| Contact dermatitis | 12 (0.02) | 6 (0.01) | 6 (0.03) | 0.1127 |
| Previous vaccine reaction history | ||||
| Local site reactionb | 1532 (2.44) | 1179 (2.65) | 353 (1.92) | < 0.0001 |
| Systemic symptomsc | 937 (1.49) | 680 (1.53) | 257 (1.40) | 0.2331 |
| Rash or blistering | 310 (0.49) | 221 (0.50) | 89 (0.48) | 0.8534 |
| Urticaria | 182 (0.29) | 112 (0.25) | 70 (0.38) | 0.0058 |
| Anaphylaxis | 87 (0.14) | 56 (0.13) | 31 (0.17) | 0.1857 |
| Past medical history | ||||
| Hypertension | 2643 (4.20) | 1930 (4.33) | 713 (3.89) | 0.0107 |
| Malignancy | 800 (1.27) | 550 (1.24) | 250 (1.36) | 0.1962 |
| Obstructive lung disease | 215 (0.34) | 134 (0.30) | 81 (0.44) | 0.0061 |
| Diabetes mellitus | 122 (0.19) | 55 (0.12) | 67 (0.37) | < 0.0001 |
| Morbid obesity | 57 (0.09) | 42 (0.09) | 15 (0.08) | 0.06335 |
SD standard deviation
aModerna vs Pfizer. Bolded p values are statistically significant (p < 0.05)
bErythema, swelling, warmth, pruritus, injection-site reaction
cFatigue, myalgia, lethargy, headache, chills, malaise, fever, gastrointestinal symptoms, lightheadedness, lymphadenopathy, arthralgia, neuropathy, dyspnea, seizure